Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2011

01.03.2011 | Original Article

CARD15 Mutations and Perianal Fistulating Crohn’s Disease: Correlation and Predictive Value of Antibiotic Response

verfasst von: Paulo Freire, Francisco Portela, Maria M. Donato, Manuela Ferreira, Paulo Andrade, Carlos Sofia

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

CARD15 mutations alter bowel immunity and increase susceptibility to Crohn′s disease (CD). However, the relation between these mutations and Crohn′s perianal fistulas has not been fully clarified.

Aims

To assess whether CARD15 mutations are associated with risk of developing Crohn’s perianal fistulas and whether these mutations are predictors of the response of perianal fistulas to antibiotics.

Methods

CARD15 mutations were investigated in 203 consecutive CD patients. Presence/absence of history of perianal fistula was recorded. Patients with history of perianal fistula were divided into two groups (with/without CARD15 mutations), and response to antibiotics was evaluated in both groups.

Results

Of the 203 patients, 60 (29.6%) showed at least one CARD15 mutation and 55 (27.1%) had history of perianal fistula. History of perianal fistula was identified in 13 (21.7%) patients with mutations and in 42 (29.4%) patients without mutations (P = 0.260). Mean age at diagnosis of first perianal fistula was similar in patients with/without CARD15 mutations (28.7 ± 9.8 versus 29.7 ± 10.1 years, P = 0.758). Average time between disease onset and diagnosis of first perianal fistula was also similar in the two groups (4.6 ± 5.1 versus 5.0 ± 5.9 years, P = 0.816). Response of perianal fistulas to antibiotics (metronidazole alone or combined with ciprofloxacin) was significantly higher in patients without CARD15 mutations (7.7% versus 40.5%, P = 0.041).

Conclusions

In CD, CARD15 mutations are not associated with risk of developing perianal fistulas or with time of their outbreak. Nevertheless, patients with perianal fistulas and CARD15 mutations showed worse response to antibiotics.
Literatur
1.
Zurück zum Zitat Schwartz DA, Herdman CR. Review article: the medical treatment of Crohn’s perianal fistulas. Aliment Pharmacol Ther. 2004;19:953–967.CrossRefPubMed Schwartz DA, Herdman CR. Review article: the medical treatment of Crohn’s perianal fistulas. Aliment Pharmacol Ther. 2004;19:953–967.CrossRefPubMed
2.
Zurück zum Zitat Hellers G, Bergstrand O, Ewerth S, Holmström B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21:525–527.CrossRefPubMed Hellers G, Bergstrand O, Ewerth S, Holmström B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21:525–527.CrossRefPubMed
3.
Zurück zum Zitat Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880.CrossRefPubMed Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880.CrossRefPubMed
4.
Zurück zum Zitat Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92–106.CrossRefPubMed Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92–106.CrossRefPubMed
5.
Zurück zum Zitat Magro F, Portela F, Lago P, et al. Crohn’s disease in a southern European country: montreal classification and clinical activity. Inflamm Bowel Dis. 2009;15:1343–1350.CrossRefPubMed Magro F, Portela F, Lago P, et al. Crohn’s disease in a southern European country: montreal classification and clinical activity. Inflamm Bowel Dis. 2009;15:1343–1350.CrossRefPubMed
6.
Zurück zum Zitat American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology. 2003;125:1503–1507.CrossRef American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology. 2003;125:1503–1507.CrossRef
7.
Zurück zum Zitat Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther. 2003;17:1145–1151.CrossRefPubMed Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther. 2003;17:1145–1151.CrossRefPubMed
8.
Zurück zum Zitat Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98–103.CrossRefPubMed Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98–103.CrossRefPubMed
9.
Zurück zum Zitat Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn’s fistulas. Dis Colon Rectum. 1996;39:1039–1043.CrossRefPubMed Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn’s fistulas. Dis Colon Rectum. 1996;39:1039–1043.CrossRefPubMed
10.
Zurück zum Zitat Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum. 2003;46:577–583.CrossRefPubMed Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum. 2003;46:577–583.CrossRefPubMed
11.
Zurück zum Zitat Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55:i36–i58.CrossRefPubMed Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55:i36–i58.CrossRefPubMed
12.
Zurück zum Zitat Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther. 2003;18:1113–1120.CrossRefPubMed Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther. 2003;18:1113–1120.CrossRefPubMed
13.
Zurück zum Zitat Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology. 1982;83:383–387.PubMed Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology. 1982;83:383–387.PubMed
14.
Zurück zum Zitat Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984;79:533–540.PubMed Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984;79:533–540.PubMed
15.
Zurück zum Zitat Turumen U, Fakkila M, Yaltonen V. Longterm outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease. Gastroenterology. 1993;104:A793. Turumen U, Fakkila M, Yaltonen V. Longterm outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease. Gastroenterology. 1993;104:A793.
16.
Zurück zum Zitat Angelberger S, Reinisch W, Dejaco C, et al. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn’s disease. Am J Gastroenterol. 2008;103:1197–1202.CrossRefPubMed Angelberger S, Reinisch W, Dejaco C, et al. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn’s disease. Am J Gastroenterol. 2008;103:1197–1202.CrossRefPubMed
17.
Zurück zum Zitat Williamson PR, Hellinger MD, Larach SW, Ferrara A. Twenty-year review of the surgical management of perianal Crohn’s disease. Dis Colon Rectum. 1995;38:389–392.CrossRefPubMed Williamson PR, Hellinger MD, Larach SW, Ferrara A. Twenty-year review of the surgical management of perianal Crohn’s disease. Dis Colon Rectum. 1995;38:389–392.CrossRefPubMed
18.
Zurück zum Zitat West RL, Van der Woude CJ, Endtz HP, et al. Perianal fistulas in Crohn’s disease are predominantly colonized by skin flora: implications for antibiotic treatment? Dig Dis Sci. 2005;50:1260–1263.CrossRefPubMed West RL, Van der Woude CJ, Endtz HP, et al. Perianal fistulas in Crohn’s disease are predominantly colonized by skin flora: implications for antibiotic treatment? Dig Dis Sci. 2005;50:1260–1263.CrossRefPubMed
19.
Zurück zum Zitat Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.CrossRefPubMed Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.CrossRefPubMed
20.
Zurück zum Zitat Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606.CrossRefPubMed Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606.CrossRefPubMed
21.
Zurück zum Zitat Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem. 2003;278:5509–5512.CrossRefPubMed Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem. 2003;278:5509–5512.CrossRefPubMed
22.
Zurück zum Zitat Kobayashi KS, Chamaillard M, Ogura Y, et al. NOD2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–734.CrossRefPubMed Kobayashi KS, Chamaillard M, Ogura Y, et al. NOD2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–734.CrossRefPubMed
23.
Zurück zum Zitat Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004;53:1658–1664.CrossRefPubMed Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004;53:1658–1664.CrossRefPubMed
24.
Zurück zum Zitat Bonen DK, Ogura Y, Nicolae DL, et al. Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology. 2003;124:140–146.CrossRefPubMed Bonen DK, Ogura Y, Nicolae DL, et al. Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology. 2003;124:140–146.CrossRefPubMed
25.
Zurück zum Zitat Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol. 2009;7:972–980. e2.CrossRefPubMed Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol. 2009;7:972–980. e2.CrossRefPubMed
26.
Zurück zum Zitat Annese V, Lombardi G, Perri F, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease—an IG-IBD study. Am J Gastroenterol. 2005;100:84–92.CrossRefPubMed Annese V, Lombardi G, Perri F, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease—an IG-IBD study. Am J Gastroenterol. 2005;100:84–92.CrossRefPubMed
27.
Zurück zum Zitat Stange EF, Travis SP, Vermeire S, et al. European Crohn’s and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 2006;55:i1–i15.CrossRefPubMed Stange EF, Travis SP, Vermeire S, et al. European Crohn’s and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 2006;55:i1–i15.CrossRefPubMed
28.
Zurück zum Zitat Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.CrossRefPubMed Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.CrossRefPubMed
29.
Zurück zum Zitat Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–530.CrossRefPubMed Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. 2002;122:512–530.CrossRefPubMed
30.
Zurück zum Zitat Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet. 2002;71:74–83.CrossRefPubMed Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet. 2002;71:74–83.CrossRefPubMed
31.
Zurück zum Zitat Lesage S, Zouali H, Cézard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845–857.CrossRefPubMed Lesage S, Zouali H, Cézard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845–857.CrossRefPubMed
32.
Zurück zum Zitat Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123:679–688.CrossRefPubMed Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123:679–688.CrossRefPubMed
33.
Zurück zum Zitat Heliö T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease. Gut. 2003;52:558–562.CrossRefPubMed Heliö T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease. Gut. 2003;52:558–562.CrossRefPubMed
34.
Zurück zum Zitat Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004;99:2393–2404.CrossRefPubMed Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004;99:2393–2404.CrossRefPubMed
35.
Zurück zum Zitat Lakatos PL, Lakatos L, Szalay F, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn’s disease: phenotype-genotype correlations. World J Gastroenterol. 2005;11:1489–1495.PubMed Lakatos PL, Lakatos L, Szalay F, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn’s disease: phenotype-genotype correlations. World J Gastroenterol. 2005;11:1489–1495.PubMed
36.
Zurück zum Zitat Radford-Smith G, Pandeya N. Associations between NOD2/CARD15 genotype and phenotype in Crohn’s disease—Are we there yet? World J Gastroenterol. 2006;12:7097–7103.PubMed Radford-Smith G, Pandeya N. Associations between NOD2/CARD15 genotype and phenotype in Crohn’s disease—Are we there yet? World J Gastroenterol. 2006;12:7097–7103.PubMed
37.
Zurück zum Zitat Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.CrossRefPubMed Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.CrossRefPubMed
38.
Zurück zum Zitat Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.PubMed Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.PubMed
39.
Zurück zum Zitat Janowitz HD, Croen EC, Sachar DB. Role of the faecal stream in the maintenance of Crohn’s colitis. Gut. 1985;26:279–284.CrossRef Janowitz HD, Croen EC, Sachar DB. Role of the faecal stream in the maintenance of Crohn’s colitis. Gut. 1985;26:279–284.CrossRef
40.
Zurück zum Zitat Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn’s disease. World J Surg. 2000;24:1258–1262.CrossRefPubMed Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn’s disease. World J Surg. 2000;24:1258–1262.CrossRefPubMed
41.
Zurück zum Zitat Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn’s perianal fistulas? Dis Colon Rectum. 2007;50:1754–1760.CrossRefPubMed Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn’s perianal fistulas? Dis Colon Rectum. 2007;50:1754–1760.CrossRefPubMed
42.
Zurück zum Zitat Nordgren S, Fasth S, Hultén L. Anal fistulas in Crohn’s disease: incidence and outcome of surgical treatment. Int J Colorectal Dis. 1992;7:214–218.CrossRefPubMed Nordgren S, Fasth S, Hultén L. Anal fistulas in Crohn’s disease: incidence and outcome of surgical treatment. Int J Colorectal Dis. 1992;7:214–218.CrossRefPubMed
43.
Zurück zum Zitat Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–1530.CrossRefPubMed Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–1530.CrossRefPubMed
44.
Zurück zum Zitat Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum. 1995;38:55–59.CrossRefPubMed Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum. 1995;38:55–59.CrossRefPubMed
45.
Zurück zum Zitat Ahrens P, Kattner E, Köhler B, et al. Mutations of genes involved in the innate immune system as predictors of sepsis in very low birth weight infants. Pediatr Res. 2004;55:652–656.CrossRefPubMed Ahrens P, Kattner E, Köhler B, et al. Mutations of genes involved in the innate immune system as predictors of sepsis in very low birth weight infants. Pediatr Res. 2004;55:652–656.CrossRefPubMed
46.
Zurück zum Zitat Brenmoehl J, Herfarth H, Glück T, et al. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med. 2007;33:1541–1548.CrossRefPubMed Brenmoehl J, Herfarth H, Glück T, et al. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med. 2007;33:1541–1548.CrossRefPubMed
47.
Zurück zum Zitat den Hartog JE, Ouburg S, Land JA, et al. Do host genetic traits in the bacterial sensing system play a role in the development of Chlamydia trachomatis-associated tubal pathology in subfertile women? BMC Infect Dis. 2006;6:122.CrossRef den Hartog JE, Ouburg S, Land JA, et al. Do host genetic traits in the bacterial sensing system play a role in the development of Chlamydia trachomatis-associated tubal pathology in subfertile women? BMC Infect Dis. 2006;6:122.CrossRef
Metadaten
Titel
CARD15 Mutations and Perianal Fistulating Crohn’s Disease: Correlation and Predictive Value of Antibiotic Response
verfasst von
Paulo Freire
Francisco Portela
Maria M. Donato
Manuela Ferreira
Paulo Andrade
Carlos Sofia
Publikationsdatum
01.03.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1331-1

Weitere Artikel der Ausgabe 3/2011

Digestive Diseases and Sciences 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.